Key Performance
More- Earnings Score: N/A
- Momentum Score: 59
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
09/30/2026, 4:54 AM • GlobeNewswire
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.
07/21/2026, 1:00 PM • GlobeNewswire
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.
07/13/2026, 1:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.
07/01/2026, 7:00 AM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.
06/29/2026, 7:00 AM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data and misrepresented the trial's operational progress and interim futility analysis timing. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
06/14/2026, 12:00 PM • GlobeNewswire
The Schall Law Firm is seeking investors to join a class action lawsuit against Immutep Limited for securities fraud. The company allegedly made false and misleading statements about its TACTI-004 trial results, claiming 'strong operational progress' while knowing the trial would fail to meet its primary efficacy endpoints. Investors who purchased securities between March 24, 2025 and March 12, 2026 are encouraged to participate.
06/12/2026, 9:00 AM • GlobeNewswire
Immutep Limited (IMMP) stockholders who purchased ADRs between March 24, 2025 and March 12, 2026 have until July 6, 2026 to seek lead plaintiff appointment in a securities class action. The lawsuit follows an 83% single-day stock decline after the company disclosed on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial for futility.
06/08/2026, 4:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false and misleading statements regarding inventory management, clinical trial prospects, and growth outlook. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in July 2026.
06/08/2026, 8:00 AM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.
06/07/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm is reminding investors who purchased Immutep Ltd. ADRs between March 24, 2025 and March 12, 2026 of an important July 6, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Immutep made false or misleading statements regarding the TACTI004 trial's status and prospects, while possessing internal clinical data suggesting increased risk of the trial failing to meet its efficacy and safety objectives.
06/05/2026, 2:52 PM • GlobeNewswire
A class action lawsuit has been filed against Immutep Limited (IMMP) for allegedly misleading investors about the viability and efficacy of its TACTI-004 drug candidate. The company claimed strong operational progress in January 2026, but in March 2026, an Independent Data Monitoring Committee recommended discontinuing the Phase III trial for futility. The stock price plummeted 83% following the announcement, from $2.76 to $0.48 per share.
06/05/2026, 1:57 PM • GlobeNewswire
Robbins LLP is investigating allegations that LKQ Corporation misled investors regarding its acquisition of Uni-Select Incorporated. The lawsuit claims LKQ falsely represented the acquisition as having minimal integration risk and assured investors the FinishMaster integration was on target, when in reality FinishMaster was losing major customers and market share. The class period spans February 27, 2023 to July 23, 2025.
06/05/2026, 1:51 PM • GlobeNewswire
Immutep announced positive Phase I interim data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers, with statistically significant pharmacodynamic activity at 7 mg/kg dose. The results support further clinical investigation in autoimmune indications such as rheumatoid arthritis.
06/04/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Immutep Ltd., POET Technologies Inc., and DNOW Inc. to join class action lawsuits. The Immutep case alleges the company made false statements about its TACTI-004 trial prospects, concealing material risks of study failure. The deadline to serve as lead plaintiff in the Immutep case is July 6, 2026.
06/02/2026, 6:41 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/01/2026
Company Profile
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.